Global pharmaceutical powerhouse Johnson & Johnson (JNJ) experienced significant financial expansion in the second quarter, with its reported sales registering an impressive 6.3% year-on-year growth to $25.53 billion, exceeding the consensus estimate by 3.5%.
Moreover, its quarterly adjusted EPS ascended 8.1% compared to the same period last year, reaching $2.80 and surpassing the consensus estimate by 6.9%.
